Antibe Therapeutics completes patient enrollment in OA knee pain trial for ATB-346

Antibe Therapeutics, a Canadian pharma company has completed enrollment of patients in a phase 2B dose-ranging, efficacy clinical trial of its lead drug candidate ATB-346 ... Read More